Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

British Journal of Cancer

Volumn 94, Issue 7, 2006, Pages 1051-1056

  Miller, W R ^a   White, S ^a   Dixon, J M ^a   Murray, J ^a   Renshaw, L ^a   Anderson, T J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitor; Breast cancer; Clinical response; Neoadjuvant therapy; Proliferation; Steroid receptors

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIAZOLES;

EID: 33645735920     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603001     Document Type: Article

References (22)

1. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168
2. Anderson TJ, Dixon JM, Murray J, Renshaw L, White S, Miller WR (2004) Early changes in tumour Ki67 expression differentiate for pathological (but not clinical) response in breast cancers treated neoadjuvantly with letrozole. Breast Cancer Res Treat 88(Suppl 1): S50
3. Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR (2002) Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 87: 334-338
4. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, Gui G, Sacks N, Ebbs SR, Allum W, Nasiri N, Dowsett M (2003) Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89: 1035-1041
5. Dixon JM (2001) Neoadjuvant endocrine therapy. In Aromatase Inhibition and Breast Cancer, Miller WR, Santen RJ (eds). pp 103-116. UK: Pub Marcel Dekker
6. Dixon JM, Love CD, Bellamy CO, Cameron DA, Leonard RC, Smith H, Miller WR (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66(3): 191-199
7. Dixon JM, Renshaw L, Murray J, Macaskill EJ, Young O, Miller WR (2005) Surgical issues surrounding use of aromatase inhibitors. J Steroid Biochem Mol Biol 95: 97-103
8. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005a) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 23(11): 2477-2492
9. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, on behalf of the IMPACT Trialists (2005b) Short-term changes in Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11(Suppl 1): 951s-958s
10. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11): 1527-1532
11. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19(18): 3808-3816
12. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63(19): 6523-6531
13. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M (1998) Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48(2): 107-116
14. Forouhi P, Walsh JS, Anderson TJ, Chetty U (1994) Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. Br J Surg 81(2): 223-225
15. Going JJ (1994) Efficiently estimated histologic cell counts. Hum Pathol 4: 333-336
16. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19): 1793-1802
17. Harper-Wynne CL, Sacks NP, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, Rayter Z, Miall S, Howes A, Salter J, Hills MJ, Lowe FM, A'Hern R, Nasiri N, Doody D, Iqbal J, Dowsett M (2002) Comparison of the systemic and intratumoural effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20(4): 1026-1035
18. Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR (2002) MIB-1 assessments in breast cancers. Breast 11(3): 252-256
19. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ (2003) Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 39(4): 462-468
20. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole vs tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
21. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39(16): 2318-2327
22. Santen RJ, Song RX, Zhang Z, Yue W, Kumar R (2004) Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 10(1 Part 2): 337S-345S